Articlenpj antimicrobials and resistance2026
Candidozyma auris-infected Galleria mellonella larvae: the effect of the humanized monoclonal antibody Dia-T51 and its synergy with amphotericin B.
Article in npj antimicrobials and resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Fungal infections pose a major worldwide health risk, as newly emerging pathogens and the increasing spread of drug resistance are now severely challenging current therapeutic and diagnostic tools. Candidozyma auris embodies both of these aspects as it is an urgent threat that is resistant to several antifungal classes. The lack of effective drugs is driving the development of innovative strategies, among them monoclonal antibodies. This study investigates the in vivo and ex vivo safety and efficacy of the humanized monoclonal antibody Dia-T51, administered alone or in combination with amphotericin B (AMB), in Galleria mellonella model. Against C. auris infection, Dia-T51 demonstrated good therapeutic efficacy and provided near-complete protection when used prophylactically. The synergy between Dia-T51 and AMB observed in vitro was confirmed in vivo, resulting in enhanced larval survival and a significant reduction in fungal burden. The results strengthen the profile of Dia-T51 as a promising biological agent against fungal infections both for its standalone potential (via direct inhibition and immune-mediated mechanisms) and for its ability to amplify the efficacy of conventional antifungals.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.